Literature DB >> 19837908

Influence of development, HIV infection, and antiretroviral therapies on the gene expression profiles of ABC transporters in human lymphocytes.

Carole Giraud1, Sandra Manceau, Xavier Declèves, François Goffinet, Jean-Pierre Morini, Hélène Chappuy, Frédéric Batteux, Sandrine Chouzenoux, Salah Yousif, Jean-Michel Scherrmann, Stéphane Blanche, Jean-Marc Tréluyer.   

Abstract

The efficacy of drugs acting on lymphocytes like anticancer, immunosuppressive, and antiretroviral drugs depends on their intracellular concentrations, which could be modulated by membrane efflux pumps belonging to the ABC transporter superfamily. The gene expression profiles of 6 main ABC transporters (MDR1, MRP1, MRP3, MRP4, MRP5, and BCRP) were established in lymphocytes from birth to adulthood using blood samples from 57 children and 15 adults (34 and 5 HIV-infected, respectively). Gene expression levels were quantified by quantitative RT-PCR. In adults, the MRP1 gene had the highest expression, followed by the MRP5 gene. BCRP and MRP4 genes were significantly higher expressed at birth than after 1 month of life. Neither HIV infection nor antiretroviral therapies modulated the gene expression profiles of ABC transporters. In conclusion, drugs that are substrates of BCRP and MRP4, like zidovudine, may have an altered efficacy in newborns.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837908     DOI: 10.1177/0091270009343696

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  8 in total

Review 1.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

2.  Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.

Authors:  Sharon M Seifert; Xinhui Chen; Amie L Meditz; Jose R Castillo-Mancilla; Edward M Gardner; Julie A Predhomme; Carolyn Clayton; Gregory Austin; Brent E Palmer; Jia-Hua Zheng; Brandon Klein; Becky J Kerr; L Anthony Guida; Caitlin Rower; Joseph E Rower; Jennifer J Kiser; Lane R Bushman; Samantha MaWhinney; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2016-09-19       Impact factor: 2.205

3.  The effects of human immunodeficiency virus infection on the expression of the drug efflux proteins P-glycoprotein and breast cancer resistance protein in a human intestine model.

Authors:  Kelstan Ellis; Jerry W Marlin; Tracey A H Taylor; Sylvia Fitting; Kurt F Hauser; Greg Rice; MaryPeace McRae
Journal:  J Pharm Pharmacol       Date:  2014-12-31       Impact factor: 3.765

4.  Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.

Authors:  Caroline Barau; Valérie Furlan; Dominique Debray; Anne-Marie Taburet; Aurélie Barrail-Tran
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 5.  Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV.

Authors:  Nomusa M Zondo; Parveen Sobia; Aida Sivro; Sinaye Ngcapu; Veron Ramsuran; Derseree Archary
Journal:  Front Genet       Date:  2022-09-29       Impact factor: 4.772

Review 6.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

7.  Differential regulation of hepatic organic cation transporter 1, organic anion-transporting polypeptide 1a4, bile-salt export pump, and multidrug resistance-associated protein 2 transporter expression in lymphocyte-deficient mice associates with interleukin-6 production.

Authors:  Connor E Bodeman; Anika L Dzierlenga; Catherine M Tally; Ryan M Mulligan; April D Lake; Nathan J Cherrington; Susan C McKarns
Journal:  J Pharmacol Exp Ther       Date:  2013-08-08       Impact factor: 4.030

8.  Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells.

Authors:  Narasimha M Midde; Namita Sinha; Pradeep B Lukka; Bernd Meibohm; Santosh Kumar
Journal:  PLoS One       Date:  2017-02-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.